Kura Oncology stock reports a 128,250-share option grant

Kura Oncology stock closed at USD 10.53 on Nasdaq on October 6, 2026, down 0.85 percent on the session. The latest company event was an inducement grant covering options for 128,250 shares to nine new employees, with an exercise price of USD 10.65.

Employee grants mark October update

GlobeNewswire reported on October 2, 2026, that Kura approved the options on October 1 under its 2023 Inducement Option Plan. The awards vest over four years, with 25 percent vesting after one year and the remainder vesting monthly over the following 36 months.

The grant price of USD 10.65 was above the October 6 closing price by USD 0.12. That places the employee award near the market level while adding a potential dilution item for shareholders to track.

KOMZIFTI creates commercial traction

Kura's second-quarter 2026 operating picture combines a new product contribution with continuing losses. According to the Yahoo Finance transcript dated August 12, 2026, KOMZIFTI generated USD 9.1 million in net product revenue in the second quarter, compared with zero in the second quarter of 2025.

The same quarter produced a net loss of USD 68.3 million, wider than the USD 66.1 million loss in Q2 2025. Collaboration revenue also fell to USD 11.8 million from USD 15.3 million, making product uptake the central commercial variable for the oncology company.

Management maintained collaboration revenue guidance of USD 45 million to USD 55 million for fiscal year 2026, according to the Yahoo Finance transcript. Cash equivalents and short-term investments stood at USD 519 million on June 30, 2026, while anticipated Kyowa Kirin payments of USD 180 million were expected to fund the ziftomenib AML program through its first top-line Phase 3 results in 2028.

Analysts see a wider valuation gap

Investing.com reported on October 5, 2026, that UBS reiterated a Buy rating and a USD 15.00 price target. The report also cited JPMorgan's USD 30.00 target and Citizens' USD 24.00 target, with each view tied to early KOMZIFTI launch execution.

MarketBeat listed a Moderate Buy consensus from 12 analysts, including 10 Buy ratings, one Hold and one Sell, with an average price target of USD 25.40. The wide gap between that target and the October 6 close reflects the market's dependence on future commercial execution rather than current earnings.

KURA stays below its yearly high

KURA's October 6 range was USD 10.34 to USD 10.89, with volume of 1.3 million shares. The 52-week range was USD 7.36 to USD 13.90, and the market capitalization was USD 944.8 million as of October 6, 2026.

More news and analyses on Kura Oncology stock